Neurohacker Collective, LLC – Trademark Portfolio
Entity Type: 16
Neurohacker Collective, LLC holds 42 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 38 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 2 Nice Classification classes. Currently, 32 trademarks are registered. Notable registered marks include QLS, N H C, ETERNUS, SMARTSEED, and FUEL FOCUS. The owner is based in Carlsbad, CA.
5946 Priestly Drive, Suite 104
Carlsbad, CA 92008
Showing of trademarks Trademarks
Trademark Classifications
Neurohacker Collective, LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does Neurohacker Collective, LLC have?
Neurohacker Collective, LLC has 42 U.S. trademarks filed with the USPTO. Of these, 32 registered, 9 abandoned, 1 cancelled.
What trademark classes does Neurohacker Collective, LLC file in?
Neurohacker Collective, LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Neurohacker Collective, LLC's most well-known trademarks?
Neurohacker Collective, LLC's registered trademark portfolio includes well-known marks such as QLS, N H C, ETERNUS, SMARTSEED, and FUEL FOCUS. These are among 32 currently registered trademarks in the portfolio.
What is Neurohacker Collective, LLC's trademark registration success rate?
Neurohacker Collective, LLC has a 76% trademark registration rate, with 32 out of 42 resolved applications resulting in successful registration. Currently, 0 applications are pending review.